

AD _____

Award Number: DAMD17-01-1-0332

TITLE: Expression of Metabolic and Apoptotic Genes During Treatment with
Chemopreventive Agents for Breast Cancer

PRINCIPAL INVESTIGATOR: Yongjian Lu, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota
Minneapolis, MN 55455-2070

REPORT DATE: July 2005

TYPE OF REPORT: Annual Summary

20060213 160

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-07-2005		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 Jul 2004 – 1 Jun 2005	
4. TITLE AND SUBTITLE Expression of Metabolic and Apoptotic Genes During Treatment with Chemopreventive Agents for Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-01-1-0332	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yongjian Lu, Ph.D. E-mail: luxxx079@tc.umn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Minnesota Minneapolis, MN 55455-2070				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Two studies related to breast cancer prevention were conducted: 1) The effects of treatment of female Sprague-Dawley rats with indole-3-carbinol (I3C), tamoxifen (TAM) or TAM+I3C on caspase activities in the mammary gland and mammary tumors induced with 7,12-dimethylbenz[α]anthracene (DMBA). Activities of caspase-3+7, -6 and -9 in the mammary gland of tumor-free DMBA-initiated rats were up-regulated by a 14 to 58 treatments with I3C. DMBA initiation was found to reduce the activities of caspase-3+7 and -8 in the mammary gland. 2) The effects of treatment of rats with 3,3'-diindolylmethane (DIM), the dimer of I3C formed in gastric acid, on the gene expression level of hepatic cytochrome P450s (CYPs) involved in estrogen metabolism. The results indicated that treatment with Phenobarbital (PB), a relevant inducer, increased mRNA expression of CYP2B1/2 significantly and 3A1.2 insignificantly, and treatment with DIM insignificantly up-regulated hepatic mRNA levels of CYP1A1 and 2B1/2. When combined with PB, treatment with DIM significantly induced mRNA level of CYP1A1, and at low dose level of DIM, CYP2B1, and 3A2. These two studies suggested the prevention of mammary tumorigenesis by I3C and DIM may be explained by their effects on apoptosis and estrogen metabolism.					
15. SUBJECT TERMS Breast cancer, chemoprevention, indole-3-carbinol, tamoxifen, 3,3'-diindolylmethane, cytochrome P450, apoptosis, caspase					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 11	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	7
References.....	7
Appendices.....	9

Introduction

Indole-3-carbinol (**I3C**) is a product of autolysis from glucobrassicin in cruciferous vegetables. It is condensed to 3,3'-diindolylmethane (**DIM**) and other products in gastric acid. I3C and DIM have been found effective in suppression of breast cancer *in vivo* and *in vitro* (Bradlow *et al.*, 1991; Chen *et al.*, 1998; Firestone *et al.*, 2003).

Previous studies from this laboratory showed that caspase activities in the mammary gland were increased by short-term treatment of rats with I3C (Zhang and Malejka-Giganti, 2003). It might have been due to the promotion by I3C of Bax translocation to mitochondria to induce apoptosis (Sarkar *et al.*, 2003). Tamoxifen (TAM) has also been reported to induce caspase activities preceding apoptosis in rat mammary tumors *in vivo* as well as in both estrogen receptor-negative and -positive human breast cancer cells *in vitro* (Mandlekar *et al.*, 2000). Therefore, the preventive effects on breast cancer by I3C may be ascribed to its activation of caspase cascade from caspase-8 (**C8**) and/or caspase-9 (**C9**) to downstream effector caspase-3 (**C3**), caspase-6 (**C6**) and caspase-7 (**C7**). Hence, I3C in an adjuvant therapy with TAM may cooperatively or synergistically inhibit tumorigenesis by inducing apoptosis in mammary glands and tumors. Therefore, caspase activities in the mammary gland and 7,12-dimethylbenz[*a*]anthracene (DMBA)-initiated mammary tumors were examined upon treatment of rats with I3C and/or TAM.

Modulations of hepatic phase I and phase II enzymes in detoxification of carcinogens such as estradiol may be another mechanism of anti-mammary tumorigenesis by I3C or DIM (Bradlow *et al.*, 1991; Wortelboer *et al.*, 1992). Whether DIM alters the expression of phase I enzymes at gene level is still unclear. In this study, hepatic mRNA levels of cytochrome P-450 (CYP) were assayed after treatment of rat with DIM and/or phenobarbital (PB), which is an inducer of hepatic CYPs involved in metabolism of estrogens.

Body

Study design

1. Two weeks after one oral dose of 65 mg/kg bw of DMBA, 9-wk-old female Sprague-Dawley rats were divided into four groups and treated 3 times per week, up to 58 times, with: (1) Vehicle I of TAM (Veh I, 10% ethanol in olive oil at 0.1 ml/rat, s.c.) + Vehicle II of I3C (Veh II, 20% ethanol in olive oil at 2.5 ml/kg bw, i.g.), (2) TAM (10 µg per rat in 50 µl Veh I, s.c.) + Veh II, (3) Veh I + I3C (250 mg/kg in Veh II, i.g.) and (4) TAM + I3C as above. Control (non-DMBA) rats also consisted of four groups treated as above. The rats were sacrificed when tumors reached volume of about 1 cc. The control and non-tumor bearing DMBA-initiated rats from each treatment group were also sacrificed at the corresponding time intervals. The mammary glands and tumors were isolated for histological evaluation and protein extraction. Caspase activities of C3+7, C6, C8 and C9 were measured using modified colorimetric caspase assay system (Promega, USA). The mean natural logarithms of activity $\pm$ standard deviation were analyzed using a one-way analysis of variance (SPSS, USA) to compare the effects of different treatment regimens after a short-term (a total of 8 treatments within 2.6 weeks) or a long-term (from 14 to 58 treatments during ~ 20 weeks) administration. The significance level was set at $P=0.05$.

2. Seven-wk-old female SD rats were treated with either DIM (8.4 or 42 mg/kg b.wt.) or vehicle (20% ethanol in olive oil) by oral *gavage* and either PB (75 mg/kg b.wt.) or saline by i.p. injection (2.5 ml/kg b.wt) once daily for 4 consecutive days. Rats were terminated 24 hr after the last treatment and a small portion of liver was snap frozen in liquid for total RNA isolation using TRIzol reagent (Invitrogen). First-strand cDNA was synthesized by pre-incubating 5 µg of total RNA, 1.25 µg of oligo(dT)₁₅ primers, 25 nmole of each dNTP at 65°C for 5 min followed by incubation at 50°C for 1 hr with 5 mM DTT, 500 U of Superscript III reverse transcriptase and 10 µl of 5X reaction buffer (Invitrogen), in a total volume of 50 µl. The cDNA levels of CYPs were detected by real-time PCR with specific primer pairs that flank in each side of intron-extron junctions and amplify fragments between 100bp and 150 bp in length. The 25 µl PCR reaction containing 12.5 µl of Platinum SYBR Green qPCR SuperMix-UDG, 0.5 µl of ROX reference dye (Invitrogen), 150 nM each primer and 1 µl of reverse transcription reaction mixture was programmed as 1 cycle at 50°C for 2 min and 95°C for 2 min, 50 cycles at 95°C for 15 sec and 60°C for 30 sec. The CYP mRNA level was expressed relative to 1,000 copies of beta-actin mRNA, the internal control.

Results

1. Effects of treatment of rats with I3C and/or TAM on caspase activities in the mammary gland and malignant mammary tumor (Fig. 1)

After a short-term treatment (8 treatments within 2.6 weeks), the level of C3+7 activity was greater ($P=0.072$) and the level of C8 activity was significantly greater ($P=0.004$) in the mammary gland (MG) of non-DMBA rats than those in the mammary gland of tumor-free [MG(t-)] DMBA-initiated rats, irrespective of treatment regimen.

In the mammary gland of tumor-free [MT(t-)] DMBA-initiated rats, the levels of all caspase activities were higher in I3C-treated than vehicle-treated group; and those in TAM+I3C-treated group were higher than those of TAM-treated one but lower than those of I3C-treated group. In the mammary gland (MG) of non-DMBA rats, the levels of all caspase activities were the highest in TAM+I3C-treated group. None of those differences was significant.

During a long-term treatment (from 14 through 58 treatments), the levels of all caspase activities were significantly greater in mammary tumor than those in the mammary gland of rats with or without DMBA-initiation ($P<0.001$). The levels of C3+7 and C8 activities were significantly greater in the mammary gland of non-DMBA rats than those in both MG(t-) and MG(t+) of DMBA-initiated rats ($P<0.001$). The level of C8 activity was significantly greater ($P<0.001$) in the mammary gland of tumor-bearing [MG(t+)] than tumor-free [MG(t-)] DMBA-initiated rats and the level of C9 activity was in the opposite way ($P=0.038$).

In the mammary gland of tumor-free [MG(t-)] DMBA-initiated rats, the level of C3+7 activity was significantly higher in I3C-treated group ($P=0.024$) and higher in TAM+I3C-treated group ($P=0.065$) than that in vehicle-treated group; the level of C6 activity was higher ($P=0.06$) in I3C-treated group than that in vehicle-treated group; the level of C9 activity in I3C-treated group was significantly higher than that in vehicle-treated group ($P=0.01$) and higher than that in TAM-treated group ($P=0.075$). However, compared to treatment with vehicle, those with I3C and/or TAM did not significantly change the levels of caspase activity in mammary tumors (MT), mammary gland (MG) of non-DMBA rats or tumor-bearing [MG(t+)] DMBA-initiated rats.

The treatment phase or rat age associated with the levels of caspase activities. Generally, the number of treatment with TAM effected the levels of C3+7 and C9 activity ($P=0.041$ and 0.052 , respectively) and the number of treatment with I3C effected the levels of C3+7, C6 and C9 activity ($P=0.047$, 0.044 and 0.022 , respectively). Such affects were considered in all the above comparisons.

2. Effects of a short-term treatment of rats with PB and/or DIM on the hepatic CYP mRNA expression (Fig. 2)

Treatment with PB up-regulated the hepatic mRNA level of CYP2B1 ($P=0.055$) and significantly of 2B2 ($P=0.004$). It insignificantly up-regulated the expression of CYP3A1 and 3A2, but when combined with lower dose level and both dose levels of DIM, treatment with PB significantly up-regulated the mRNA levels of CYP3A1 and 3A2, respectively. Treatment with PB possibly up-regulated CYP1A1 transcription only when it was combined with higher dose level of DIM. Treatment with PB alone significantly down-regulated the mRNA level of CYP2E1 in liver ($P=0.03$, data not shown).

Treatment with DIM up-regulated the hepatic mRNA levels of CYP1A1, 2B1 and 2B2. The induction was greater at higher dose level of DIM than that at the lower dose level, but none of them were significant. However, when combined with PB, treatment with both dose levels of DIM significantly induced mRNA level of CYP1A1 and with lower dose level of DIM significantly induced those of CYP2B1 and CYP3A2. Treatment with DIM alone insignificantly down-regulated hepatic mRNA levels of CYP3A1/2 and apparently decreased CYP2E1 mRNA level (data not shown).

Key Research Accomplishments

- Initiation of mammary tumorigenesis with DMBA suppressed caspase-8 and slightly later (~3 weeks after initiation) caspase-3&7 activities in the mammary gland.
- Treatment of rats with I3C increased caspase activities in the mammary gland, especially the caspase-3&7 and caspase-8 activities in mammary gland of tumor-free DMBA-initiated rats in a long-term treatment.
- Treatment of rats with PB induced hepatic mRNA levels of 2B1/2 and 3A1/2 and reduced the level of CYP2E1.
- Treatment with DIM induced hepatic mRNA levels of CYP1A1 especially when combined with PB, and when combined with PB, it induced CYP2B1 and 3A2 at low dose level.

Reportable Outcomes

Caspase activities: Manuscript in preparation, intended submission to Cancer Epidemiology, Biomarkers and Prevention.

CYP mRNA expression:

1. Poster at the 96th AACR Annual Meeting, Anaheim, CA, April 16-20, 2005 (Appendices: Abstract)
2. Poster at the Engebretson Symposium on Drug Discovery and Development In Cancer Experimental Therapeutics, Minneapolis, MN, June 9, 2005
3. Poster at the VA Medical Center Research Day, Minneapolis, MN, June 24, 2005

Conclusions

The levels of caspase activities in the mammary tumor were much higher than those in the mammary gland and were not affected by treatment of rats with TAM and/or I3C.

Initiation of rats with DMBA significantly decreased the activities of C8 in mammary gland and later, about three weeks after initiation, decreased the activities of C3+7, suggesting that the mechanism of tumorigenesis by DMBA may depend on inhibition of extrinsic pathway of apoptosis, i.e., DMBA suppresses the activation of C8 and subsequently the activities of effector C3+7, saving abnormal cells from apoptosis and offering them more chances to survive and propagate. Comparing the levels of caspase activities in mammary gland of tumor-bearing rats to those of tumor-free DMBA-initiated ones, C8 activity was greater in the former [MG(t+)] and C9 greater in the latter [MG(t-)], indicating that the existence of mammary tumor increased the level of C8 activity and decreased that of C9 in other parts of mammary gland. It is a possible systemic response to tumor by the body, or tumor itself suppresses tumorigenesis in other parts of the body through activating transmembrane death receptors and subsequently the extrinsic pathway of apoptosis.

In the mammary gland of tumor-free but not tumor-bearing DMBA-initiated rats, treatment with I3C increased caspase activities, and even to a greater extent after a long-term treatment, implying that I3C may be protective in suppressing mammary tumorigenesis by increasing apoptosis before tumors have fully developed. However, no additive or synergistic effects on caspase activities were observed by treatment with TAM+I3C. It suggests a prophylactic value of I3C in mammary tumor prevention.

A short-term treatment of rats with PB preferentially up-regulated mRNA expression of hepatic CYP2B1 and CYP2B2 and to a lesser extent of CYP3A1/2. Treatment with DIM insignificantly up-regulated mRNA levels of hepatic CYP1A1 and 2B1/2 and decreased those of CYP3A1/2. The treatment of rat with PB+DIM increased hepatic mRNA expression of CYP1A1 due to the effect of DIM, and increased the expression of CYP2B1/2 and 3A1/2 basically due to PB. Therefore, treatment with DIM has moderate effects on the expression levels of phase I enzymes and may subsequently change the metabolism of estrogens.

References

- Bradlow HL, Michnovicz J, Telang NT, Osborne MP. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. *Carcinogenesis*. 1991, 12(9):1571-4.
- Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldanes LF. Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3'-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. *Biochem Pharmacol*. 1999, 58(5):825-34
- Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3,3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. *J Nutr*. 2003, 133(7 Suppl):2448S-2455S.

Mandlekar S, Hebbar V, Christov K, Kong AN. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. *Cancer Res.* 2000, 60(23):6601-6.

Sarkar FH, Rahman KM, Li Y. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. *J Nutr.* 2003, 133(7 Suppl):2434S-2439S.

Wortelboer HM, de Kruif CA, van Iersel AA, Falke HE, Noordhoek J, Blaauboer BJ. Acid reaction products of indole-3-carbinol and their effects on cytochrome P450 and phase II enzymes in rat and monkey hepatocytes. *Biochem Pharmacol.* 1992, 43(7):1439-47.

Zhang, X. and Malejka-Giganti, D. Effects of treatment of rats with indole-3-carbinol on apoptosis in the mammary gland and mammary adenocarcinomas. *Anticancer Res.* 2003, 23: 2473-9.

Appendices




Fig. 1. Caspase activities (arithmetic means $\pm$ SD) in mammary gland (MG) of non-DMBA rats and mammary gland with tumor [MG(t+)] or without tumor [MG(t-)] and malignant mammary tumors (MT) of DMBA-initiated rats after a short-term or long-term treatment with I3C and/or TAM. The data are presented as the quantity of p-nitroaniline (nmol) liberated per mg protein per 24 hr. a, $P < 0.05$ vs. corresponding long-term treatment groups of MG(t-) and MG(t+) of DMBA-initiated rats; b, $P < 0.05$ vs. corresponding short-term treatment groups of MG(t-); c, $P < 0.05$ vs. corresponding tumor-bearing or -free groups; d, $P < 0.05$ vs. corresponding vehicle-treated group.




Fig. 2. Effects of treatment of rats with DIM, PB or DIM+PB on CYP mRNA expression in the liver. The data are presented as the mean $\pm$ SD. a, $P < 0.05$ vs. corresponding non PB-treated group; b, $P < 0.05$ vs. PB-treated group.

Abstract for 96th AACR Annual Meeting, Anaheim, CA, April 16-20, 2005

Inhibition by 3,3'-diindolylmethane *in vivo* of 2-, 4- and 6 β -hydroxylations of 17 β -estradiol by rat hepatic microsomes: a potential mechanism for suppression of mammary cancer

Yongjian Lu, Daniel R. Parkin, Danuta Malejka-Giganti

Veterans Affairs Medical Center and Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN.

Cancer-preventive properties of the components of cruciferous vegetables including indoles have been studied extensively. 3,3'-Diindolylmethane (DIM) is a major product formed in the acid pH of the stomach after oral intake of indole-3-carbinol. DIM has been reported to inhibit activities of CYP1A1 and CYP2B1/2 *in vitro* (Stresser *et al*, *J Biochem Toxicol*, 1995). Since phenobarbital (PB)-inducible CYP2B1/2 catalyzes 4-, 6 α - and 6 β -hydroxylations of 17 β -estradiol (E2) yielding putative carcinogenic metabolites of E2, we investigated whether treatment of female Sprague-Dawley rats with DIM affects the PB-inducible CYP mRNA expression, CYP activities and metabolism of E2. At 50 days of age, rats were treated with PB (75 mg/kg b.wt. by intraperitoneal injection), DIM (42 mg/kg b.wt. by oral gavage), PB+DIM or the respective vehicles for four consecutive days. On day 5, rats were killed and the livers were excised and processed for analyses of CYP (1A1, 1A2, 2B1, 2B2, 3A1 and 3A2) mRNA expression by real-time PCR, CYP activities by *O*-dealkylation of alkoxyresorufins and nifedipine oxidation (NIFOX), and [4-¹⁴C]-E2 metabolism by HPLC and radiometry. Treatment of rats with DIM increased the relative mRNA expression level of CYP1A1 (9-fold), CYP2B1 (6-fold) and CYP2B2 (4-fold). Treatment with PB preferentially induced mRNA expression of CYP2B1 (505-fold) and CYP2B2 (34-fold), and increased that of CYP3A2 (2-fold). Treatment with DIM increased EROD (CYP1A1), BROD and PROD (CYP2B1/2) activities 8-, 27- and 9-fold, respectively. Treatment with PB increased EROD, BROD, PROD and NIFOX (CYP3A1/2) activities (2.2-, 725-, 311- and 1.5-fold, respectively) and the total P450 level (1.8-fold). Neither DIM nor PB treatment affected MROD (CYP1A2) activity. Treatment with DIM increased the rates of formation of 2-OH-E2 (1.5-fold) and 6 β -OH-E2 (2.2-fold) from E2, while PB increased the rates of formation of 2-OH-E2, 2-OH-E1, 4-OH-E2, E3, 6 α -OH-E2, 6 β -OH-E2 and 6(α + β)-OH-E1 (3.6-, 16-, 3.1-, 4.4-, 5.4-, 32- and 2.5-fold, respectively) from E2. Treatment with DIM+PB decreased the rates of formation of 2-OH-E2, 2-OH-E1, 4-OH-E2, 6 β -OH-E2 and 6(α + β)-OH-E1 from E2 by 28, 63, 43, 47 and 49%, respectively, relative to PB-treated rats, indicating partial inhibition by DIM *in vivo* of the PB-induced increases in the rates of oxidation of E2. This was not associated with down-regulation of either the mRNA expression or activity of the CYPs that reportedly catalyze these hydroxylations. These findings suggest that DIM might inhibit a CYP not analyzed in this study or that DIM might be a substrate for E2-metabolizing CYP(s), and thus decreases its capacity to hydroxylate E2. The mechanism of inhibition by DIM *in vivo* of E2 oxidations deserves further investigation since E2 plays an important role in the promotion of mammary carcinogenesis. Inhibition by DIM of adverse E2 reactions, particularly 4-, 6 α - and 6 β -hydroxylations, might offer the desired means of suppressing mammary cancer.

[This research was supported by the Department of Veterans Affairs and the Department of Defense.]